Form 4: Mersana Therapeutics Acquired: Executive Equity Converted

Mersana Therapeutics, Inc. has been acquired by Day One Biopharmaceuticals, Inc., resulting in the conversion of executive Ashish Mandelia's equity holdings into cash and contingent value rights.

Summary

• Mersana Therapeutics, Inc. (MRSN) was acquired by Day One Biopharmaceuticals, Inc. (Parent) through its subsidiary, Emerald Merger Sub, Inc. (Purchaser), effective January 6, 2026.
• The acquisition was executed via a tender offer, where shares of Mersana's common stock were exchanged for an Offer Price.
• The Offer Price consisted of $25.00 per share in upfront cash consideration, plus one non-tradeable contingent value right (CVR) per share.
• Each CVR represents the right to receive certain contingent milestone payments of up to an aggregate of $30.25 per CVR in cash, subject to the achievement of specified milestones.
• Following the tender offer, Purchaser merged with Mersana, making Mersana a wholly-owned subsidiary of Day One Biopharmaceuticals, Inc.
• Ashish Mandelia, VP, Chief Accounting Officer, disposed of 2,300 shares of common stock, which were converted into the Offer Price.
• Mandelia's 'Cash-Out Options' (exercise price less than $25.00) became fully vested, were cancelled, and converted into the right to receive the Offer Price minus the exercise price.
• Mandelia's 'OTM Options' (exercise price equal to or greater than $25.00) became fully vested and exercisable for a limited period; those not exercised by the Last Exercise Date were cancelled without consideration.
• Mandelia's Restricted Stock Units (RSUs) were automatically cancelled and converted into the right to receive the Offer Price.

Sentiment

Score: 7

Explanation: The sentiment is generally positive as the acquisition provides a definitive cash value and potential upside for shareholders through CVRs, representing a successful exit for the company. However, the cancellation of unexercised out-of-the-money options without consideration introduces a minor negative aspect for some equity holders.

Positives

• The acquisition provides a clear and immediate cash value of $25.00 per share for Mersana shareholders.
• Shareholders also receive contingent value rights (CVRs) offering potential additional upside of up to $30.25 per CVR, aligning their interests with future success.
• The transaction provides a definitive exit for public shareholders of Mersana Therapeutics.

Negatives

• Out-of-the-money (OTM) stock options with an exercise price equal to or greater than the $25.00 upfront cash consideration were cancelled without consideration if not exercised by the specified deadline.
• Mersana Therapeutics, Inc. ceases to be an independent publicly traded company, becoming a wholly-owned subsidiary.

Risks

• The full value of the contingent value rights (CVRs), up to $30.25 per CVR, is not guaranteed and is dependent on the achievement of specific, undisclosed milestones.
• The CVRs are non-tradeable, limiting liquidity and the ability to realize their value before milestones are met.

Future Outlook

Mersana Therapeutics, Inc. is now a wholly-owned subsidiary of Day One Biopharmaceuticals, Inc. The future outlook for the former Mersana assets and programs is integrated into Day One's strategic plans, with potential additional payments to former Mersana shareholders contingent on the achievement of specific milestones related to the CVRs.

Industry Context

This acquisition is characteristic of the biotechnology and pharmaceutical industry, where larger companies often acquire smaller firms with promising pipelines to expand their portfolios. The use of Contingent Value Rights (CVRs) is a common mechanism in such M&A deals, allowing the acquiring company to share future development risks and rewards with the target company's former shareholders, particularly when the value of pipeline assets is uncertain or milestone-dependent.

Comparison to Industry Standards

• The structure of this acquisition, combining an upfront cash payment with contingent value rights (CVRs), is a standard approach in biotech M&A, particularly for companies with assets in clinical development.
• Similar deals include acquisitions where milestone payments are tied to regulatory approvals, commercialization, or specific sales targets, such as the acquisition of Synageva BioPharma by Alexion Pharmaceuticals or the acquisition of Portola Pharmaceuticals by Alexion, both of which included CVR components.

Management Changes

Corporate Governance

Stakeholder Impact

• Shareholders: Received $25.00 per share in cash and one non-tradeable contingent value right (CVR) per share, with potential for up to an additional $30.25 per CVR.
• Employees (including Ashish Mandelia): Equity holdings were converted as per the merger agreement, with common stock, cash-out options, and RSUs converted to cash and CVRs, while out-of-the-money options were cancelled if not exercised.
• Mersana Therapeutics as an entity: Now operates as a wholly-owned subsidiary of Day One Biopharmaceuticals, Inc., integrating its operations and strategic direction with the parent company.

Next Steps

• Day One Biopharmaceuticals, Inc. will continue the development and commercialization efforts for Mersana's assets.
• Former Mersana shareholders will await potential payments tied to the achievement of specified milestones for the contingent value rights (CVRs).

Key Dates

Keywords

Mersana Therapeutics, MRSN, Day One Biopharmaceuticals, Merger, Acquisition, Tender Offer, Contingent Value Right, CVR, Stock Options, Restricted Stock Units, Form 4, Beneficial Ownership